Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People with non-small cell lung cancer (NSCLC) that cannot be surgically removed, is at an advanced stage (Stage IIIB, IIIC, or Stage IV), and has continued to grow or spread after standard treatments — including platinum-based chemotherapy and, where appropriate, immunotherapy.
• People whose cancer has at least one area that can be measured on scans, according to standard measurement guidelines called RECIST v1.1.
• People who have stored tumour tissue samples available from a previous biopsy, or who are willing to have a new biopsy taken, so that the tumour can be tested for specific proteins.
• People whose tumour shows high levels of at least two out of three specific proteins — MSLN, EGFR, and HER2/ERBB2 — based on laboratory testing at the start of the trial (confirm specific thresholds with trial site).
• People with a good general level of physical functioning, rated 0 or 1 on a standard medical scale called the ECOG scale (meaning fully active or able to carry out light activity).
• People whose liver, kidneys, and blood counts are working within acceptable ranges as defined by the trial's laboratory guidelines.
• People with a life expectancy of at least 12 weeks.
• People who are not pregnant, confirmed by a negative pregnancy test if applicable, and who agree to use effective contraception for the period required by the trial.
• People who are able to understand the trial information and are willing to sign a written consent form.

Who may not be able to join:

• People with brain or spinal cord involvement from their cancer that is active and not well controlled. People with previously treated and stable brain involvement may still be considered if their condition is clinically stable and they are no longer on high-dose steroid medication.
• People who have received a type of specialised cell-based gene therapy — such as CAR-T, CAR-NK, or TCR-T therapy — within the past 3 months, or any previous treatment that the trial doctor considers may increase the risk of serious side effects.
• People who have previously experienced a severe reaction called cytokine release syndrome (CRS) or a serious nervous system complication called ICANS from prior treatments.
• People with significant ongoing lung inflammation or scarring (interstitial lung disease or pneumonitis) that requires steroid treatment, or other serious uncontrolled lung conditions that could make it difficult to monitor for side effects.
• People with an active autoimmune disease that requires ongoing immune-suppressing medication (low-dose steroid replacement for hormone deficiency may be permitted — confirm with trial site).
• People with an active, uncontrolled infection, including uncontrolled HIV, active hepatitis B, or active hepatitis C.
• People with serious heart conditions, such as a recent heart attack, unstable chest pain, an uncontrolled irregular heartbeat, or reduced heart pumping function below the level set by the trial site.
• People who are pregnant or breastfeeding.
• People who are currently receiving other cancer treatments — such as chemotherapy, targeted therapy, or immunotherapy — and have not waited the required time since their last treatment as defined by the trial.
• People with any other condition that the trial doctor believes would affect their safety or their ability to participate fully in the trial.

Important: Always verify eligibility with the trial site directly before applying.